bioAffinity Technologies Enhances Lung Cancer Detection Efforts
bioAffinity Technologies, Inc. (Nasdaq: BIAF), a leader in biotechnology aiming to improve the early detection of cancer through noninvasive methods, is pleased to announce its participation in a critical presentation about the recent addition of its product, CyPath® Lung, to the Federal Supply Schedule. This addition is a significant milestone, allowing healthcare providers greater access to this innovative diagnostic tool within the Veterans Health Administration (VHA).
Introduction to CyPath® Lung
CyPath® Lung has emerged as a groundbreaking noninvasive test designed to help detect early-stage lung cancer. The VHA, which serves millions of veterans across the nation, has recognized the importance of integrating cutting-edge medical advancements into their healthcare system. The recent award reflects a commitment to enhancing the health outcomes of veterans and addresses a pressing need for early-stage lung cancer diagnostics.
The Role of the Veterans Health Administration
The VHA is known for being the largest integrated healthcare system in the U.S., serving around 9.1 million veterans annually. With more than 1,300 healthcare facilities, including over 170 medical centers and thousands of outpatient sites, the inclusion of CyPath® Lung into this system indicates a concerted effort to leverage advanced technology for better health management.
Feedback from Industry Leaders
Maria Zannes, the President and CEO of bioAffinity Technologies, commented on the importance of this partnership. The opportunity to provide CyPath® Lung to VA healthcare facilities signifies a robust chance to assist veterans in their journey towards improved health. Zannes emphasized the collaborative spirit fostered by the National Association of Veterans’ Research and Education Foundations (NAVREF) to share knowledge and resources, enhancing the reach of essential healthcare innovations.
Partnerships and Collaborative Efforts
NAVREF plays a pivotal role in creating partnerships that benefit both industry players and veterans. Rashi Romanoff, NAVREF's CEO, praised the collaboration, stressing the transformative potential of such public-private partnerships. Together, bioAffinity Technologies and the VHA aspire to enhance lung cancer detection rates, ultimately improving health outcomes for those who have served the nation.
Importance of Early Detection
Veterans face unique challenges when it comes to health, particularly concerning lung cancer, due to factors such as age, smoking history, and environmental exposures from military service. Programs like the Lung Precision Oncology Program aim to promote regular lung cancer screenings, particularly for high-risk individuals. CyPath® Lung serves a crucial function in this process, offering a reliable method to assess suspicious results from initial screening procedures.
About CyPath® Lung Technology
This innovative diagnostic tool employs advanced flow cytometry combined with artificial intelligence (AI) to analyze sputum samples for cancer indicators. By using a special fluorescent marker that targets cancer cells, CyPath® Lung can accurately identify malignancy presence, resulting in a high sensitivity and specificity rate. Recent clinical studies have shown promising outcomes, indicating that early diagnosis can significantly improve patient survival and treatment success rates.
Addressing Challenges in Lung Cancer Diagnostics
The journey towards correctly diagnosing lung cancer is often fraught with challenges, including the need for invasive procedures that may not always be necessary. CyPath® Lung addresses these concerns by providing a noninvasive alternative that bridges the gap between inconclusive screening results and invasive biopsies, enhancing patient comfort and accuracy in diagnosis.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is dedicated to pioneering noninvasive diagnosis methods for early-stage cancer and diseases affecting the lungs. With a commitment to advancing healthcare through innovative research, the company seeks to improve cancer treatment options and outcomes. The focus on diagnostic ingenuity aligns with the organization's mission to empower healthcare providers and better serve patients, particularly veterans.
Frequently Asked Questions
1. What is CyPath® Lung?
CyPath® Lung is a noninvasive diagnostic test developed by bioAffinity Technologies to help detect early-stage lung cancer through sputum analysis.
2. How does CyPath® Lung work?
The test uses advanced flow cytometry and artificial intelligence to identify malignant cell populations in patient sputum samples.
3. Why is early detection of lung cancer important for veterans?
Veterans are at higher risk for lung cancer due to various factors, including older age and environmental exposures, making early detection critical for effective treatment.
4. How does the Federal Supply Schedule impact the availability of CyPath® Lung?
The addition of CyPath® Lung to the Federal Supply Schedule allows VHA healthcare providers to access this innovative diagnostic tool more easily.
5. What are the sensitivity and specificity rates of CyPath® Lung?
Clinical studies indicate that CyPath® Lung has 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients.
